omomyc peptide FPPa-OmoMYC - Blocking Myc to treat cancer: Reflecting on two decades ofOmomyc Omomyc is the first cell-penetrating peptide targeting MYC for cancer therapy Omomyc Peptide: A Novel Therapeutic Approach Targeting Cancer

Blocking Myc to treat cancer: Reflecting on two decades ofOmomyc The omomyc peptide represents a groundbreaking advancement in cancer therapy, specifically targeting the MYC oncoprotein, a key driver of numerous cancers.Tumor penetrating peptides inhibiting MYC as a potent ... This peptide has emerged from decades of research, evolving from a laboratory tool to a promising therapeutic agent now undergoing clinical evaluationTumor penetrating peptides inhibiting MYC as a potent .... Its development signifies a major step forward in the quest for effective MYC targeting strategies.

Understanding the MYC Oncoprotein and Omomyc's Role

The MYC oncoprotein is a transcription factor that plays a crucial role in cell growth, proliferation, and differentiation. However, its dysregulation is implicated in a vast majority of human cancers, contributing to uncontrolled cell division and tumor formation.2021年3月18日—Peptomyc'sOmomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II trial to assess the efficacy and safety of a novel Myc inhibitor. For a long time, targeting MYC directly was considered a significant challenge due to its complex structure and essential cellular functions作者：F Giuntini·2025·被引用次数：3—Here, we show thatOmomyc, the only direct MYC inhibitorthat has completed a phase 1 trial, shuts down DDR genes in triple-negative breast ....

This is where the omomyc peptide (also referred to as omoMYC) comes into play. Omomyc is designed as a dominant-negative inhibitor of MYC. It functions by mimicking MYC's structure, specifically its DNA-binding domain and coiled-coil region, which are essential for its function.Monoclonal antibody specific for Omomyc, capable of suppressing Myc-induced oncogenesis. Background and Research Application Omomyc is a dominant-negative ... By binding to the same DNA sequences that MYC normally targets, omomyc effectively blocks MYC's transcriptional activity. This mechanism essentially "shuts down" the oncogenic signals driven by MYC, thereby inhibiting tumor growthInhibiting Myc in cancer using Omomyc. From defining the ....

From Lab Bench to Clinical Trials: The Evolution of Omomyc

The journey of omomyc began with its initial design as a laboratory tool to study MYC perturbation, dating back to 1998. Over the years, researchers have refined its properties and explored its therapeutic potential. A significant milestone was the demonstration that a purified Omomyc mini-protein itself possesses intrinsic cell-penetrating activity.2025年8月21日—The outcomes of this study suggest that the inhibition of c-Myc exerted byOmomyc peptidereduces significantly cell growth and migration. This means it can spontaneously enter cancer cells, a crucial characteristic for an effective therapeutic agent.作者：E Wang·2018·被引用次数：94—Herein, we describe the engineering of thedominant-negative MYC peptide (OmoMYC) linked to a functional penetrating 'Phylomer' peptide (FPPa) as a therapeutic ... This observation propelled Omomyc from a conceptual idea to a tangible therapeutic candidate.作者：E Wang·2018·被引用次数：94—Herein, we describe the engineering of thedominant-negative MYC peptide (OmoMYC) linked to a functional penetrating 'Phylomer' peptide (FPPa) as a therapeutic ...

The development has been championed by Peptomyc SL, a company dedicated to advancing Omomyc and its improved variants into clinically viable therapeutics. Their lead candidate, OMO-103, is an Omomyc-based therapy that has garnered significant attention. OMO-103 has successfully completed a Phase 1 trial, marking a critical step in its journey towards becoming a widely available treatment.WO2020187998A1 - Combination therapy with omomyc ... The OMO-103 structure has been meticulously studied to optimize its efficacy and safety profile.作者：E Wang·2019·被引用次数：94—We foundFPPa-OmoMYCto be a potent inducer of apoptosis (with IC50 from 1-2 µM) in TNBC cells with negligible effects in non-tumorigenic cells.

Clinical Efficacy and Future Prospects

The clinical trial data for OMO-103 has been highly encouraging. Early studies, including a Phase 1 trial investigating MYC targeting by OMO-103 in solid tumors, have shown promiseOmomyc(OMO-103) is a therapeutic mini-protein developed by Peptomyc SL, a spin-off company by the VHIO and Catalan Institute of Research and Advanced .... Omomyc has demonstrated the ability to reduce the ability of MYC to bind specific box sequences in promoters of MYC target genesArticle MYC inhibition by Omomyc causes DNA damage .... Furthermore, research has indicated that Omomyc inhibition can cause DNA damage in cancer cells and that OmoMYC causes the largest decreases in promoter occupancy and changes in gene expression in genes invaded by oncogenic MYC levels.

The omomyc peptide has shown potential in various cancer types. For instance, studies have explored its efficacy in breast cancer, where Omomyc has been shown to boost the response to PARP inhibitors. The Omomyc mechanism of action is being further elucidated, with ongoing research investigating its impact on DNA damage response (DDR) genes.

Beyond OMO-103, researchers are exploring other innovative delivery methods. Engineered peptide coacervates, for example, have been developed to enable efficient intracellular delivery of omoMYCMYC targeting by OMO-103 in solid tumors: a phase 1 trial. Additionally, combinations therapies are being investigated, such as linking Omomyc to antibodies like the anti-HER3 antibody in EV20/Omomyc, to create dual-targeting agents. The development of Omomyc-based cell-penetrating peptides continues to expand the therapeutic landscape.

The promise of omomyc peptide extends to its potential to induce rapid tumor regression in mouse models with minimal toxicity, a critical factor for any successful cancer therapyOmomyc Reveals New Mechanisms To Inhibit the MYC .... The observation that Recombinant Omomyc is a Cell-penetrating Peptide has been pivotal in its therapeutic development. The company Peptomyc aims to further develop the Omomyc peptide and its improved variants.Peptomyc – Developing a Myc inhibitor to treat cancer

Key Features and Benefits of Omomyc Therapy

* Direct MYC Inhibition: Omomyc is recognized as the only direct MYC inhibitor that has successfully completed a Phase 1 trial, offering a targeted approach to a challenging oncoprotein.

* Cell Penetration: The purified Omomyc mini-protein exhibits excellent intrinsic cell-penetrating properties, allowing it to effectively enter cancer cells without the need for complex delivery systems. This characteristic has been a significant advantage in its development as Omomyc is the first cell-penetrating peptide targeting MYC for cancer therapy.

* Dominant-Negative Mechanism: As a dominant-negative MYC peptide (OmoMYC), it competitively inhibits the function of endogenous MYC, thereby reducing oncogenic signaling.Blocking Myc to Treat Cancer: Reflecting on Two Decades ...

* Therapeutic Potential: Omomyc has demonstrated the ability to inhibit tumor growth and has shown promise in clinical trials for various solid tumors. The development of FPPa-OmoMYC has shown potent induction of apoptosis in triple-negative breast cancer cells.

* Reduced Proliferation and Apoptosis Induction: In some contexts, omoMYC coacervates result in reduced proliferation and apoptosis induction.

* Foundation for Future Therapies: Omomyc serves as a foundational element for developing next-generation MYC-targeted therapies, including combination treatments and novel formulations. The existence of a Monoclonal antibody specific for Omomyc further underscores its significance in cancer research.

In conclusion, the omomyc peptide represents a significant leap forward in the fight against cancer. Its unique mechanism of action, inherent cell-penetrating capabilities, and promising clinical data position it as a vital therapeutic candidate for a wide range of MYC-driven malignancies. The ongoing research and development efforts surrounding omomyc and its derivatives hold immense promise for improving patient outcomes and offering new hope for those battling cancer2016年10月26日—Expression of a dominant-negative allele of MYC, termed OmoMYC,can induce rapid tumor regression in mouse modelswith little toxicity for ....